US 12,435,337 B2
Inhibitors of expression and/or function
Alan Victor Whitmore, Bath (GB); Julie Borgel, London (GB); Amy McCarthy, Cambridge (GB); Graham Craggs, Bicester (GB); James Longden, Maidenhead (GB); Ines De Santiago, London (GB); Duncan Brown, Berkeley, CA (US); Ahmad Ali Mortazavi, London (GB); Viviana Mannella, London (GB); Muthusamy Jayaraman, Cambridge, MA (US); Alexandre Debacker, London (GB); and Adrian Mogg, Blackwater (GB)
Assigned to E-Therapeutics PLC, London (GB)
Filed by E-Therapeutics PLC, London (GB)
Filed on Apr. 19, 2024, as Appl. No. 18/640,905.
Application 18/640,905 is a continuation of application No. PCT/EP2023/064762, filed on Jun. 1, 2023.
Claims priority of provisional application 63/369,627, filed on Jul. 27, 2022.
Claims priority of application No. 2208124 (GB), filed on Jun. 1, 2022; and application No. 23155118 (EP), filed on Feb. 6, 2023.
Prior Publication US 2024/0336922 A1, Oct. 10, 2024
Int. Cl. C12N 15/11 (2006.01); C12N 15/113 (2010.01)
CPC C12N 15/1137 (2013.01) [C12N 2310/14 (2013.01); C12N 2310/322 (2013.01); C12N 2310/351 (2013.01)] 19 Claims
 
1. A method for treating diabetes in an individual, comprising administering to the individual an inhibitor of expression of B4GALT1, wherein the inhibitor is an siRNA oligomer.